; and (5) coordinate with the clearinghouse established under section 3. (d) Authorization of appropriations To carry out this section, there is authorized to be appropriated $5,000,000 for the period of fiscal years 2024 through 2028. 6. Research prioritization process for pregnant and lactating women at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (a) In general The Director of the National Institutes of Health, acting through the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (referred to in this section as NICHD ), shall carry out priority research projects on existing and new medications prescribed for pregnant and lactating women. (b) Research prioritization process The Director of the National Institutes of Health shall establish a research prioritization process to determine which proposed research projects should receive priority funding under this section. Such research prioritization process shall take into account the following factors: (1) The available evidence, including whether there is an unmet medical need or gap in scientific information relevant to treatment of pregnant and lactating women with specific diseases or conditions. (2) The feasibility of research, including the prevalence of a disease or condition in pregnant and lactating women and the availability of investigators with expertise in studying such disease or condition. (3) The potential impact of research, including the severity of the disease or condition in pregnant and lactating women, the current cost of treating the disease or condition in pregnant and lactating women, the frequency of use of the drug in pregnant and lactating women, and the availability of alternative treatments for the disease or condition in pregnant and lactating women. (c) Consultation In developing the research prioritization process described in subsection (b), the Director of the National Institutes of Health shall seek feedback from— (1) the existing research